Pharmacotherapy of mood disorders

Annual Review of Clinical Psychology

Volumn 4, Issue , 2008, Pages 53-91

  Thase, Michael E ^a   Denko, Timothey ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antidepressants; Atypical antipsychotics; Bipolar disorder; Depression; Lithium; Mood stabilizers; Valproate

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ASCENDIN; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; IMIPRAMINE; ISOCARBOXAZID; LITHIUM; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ACUTE DISEASE; AGITATION; APPETITE; APPETITE DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BLOOD PRESSURE; BLURRED VISION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIARRHEA; DISEASE COURSE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; FATIGUE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; LIVER FAILURE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MELANCHOLIA; MEMORY DISORDER; MICTURITION DISORDER; MOOD DISORDER; MUSCLE DISEASE; MYOCLONUS; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PERCEPTION DISORDER; PRIAPISM; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; TREMOR; URINE RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; LITHIUM CARBONATE; MOOD DISORDERS; SEVERITY OF ILLNESS INDEX; VALPROIC ACID;

EID: 43449101562     PISSN: 15485943     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.clinpsy.2.022305.095301     Document Type: Review

References (184)

1. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. 2005. Agitated "unipolar" depression reconceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J. Affect. Disord. 85(3):245-58
2. Allen MH, Hirschfeld RM, Wozniak PJ, Baker JD, Bowden CL. 2006. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am. J. Psychiatry 163:272-75
3. Altshuler LL, Suppes T, Black D, Nolen WA, Keck PE Jr, et al. 2003. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am. J. Psychiatry 160(7):1252-62
4. Altshuler LL, Suppes T, Black DO, Nolen WA, Leverich G, et al. 2006. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am. J. Psychiatry 163(2):313-15
5. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N. Engl. J. Med. 356(26):2684-92
6. Am. Psychiatr. Assoc. 2000a. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Am. Psychiatr. Assoc. 4th ed., text rev.
7. Am. Psychiatr. Assoc. 2000b. Practice guideline for the treatment of patients with major depressive disorder. Am. J. Psychiatry 157(Suppl. 4):1-45 (rev.)
8. Am. Psychiatr. Assoc. 2002. Practice guideline for the treatment of patients with bipolar disorder. Am. J. Psychiatry 159(Suppl. 4):3-50 (rev.)
9. Anderson IM. 1998. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety 7(Suppl. 1):11-17
10. Andrade C, Bhakta SG, Singh NM. 2006. Controversy revisited: selective serotonin reuptake inhibitors in paediatric depression. World J. Biol. Psychiatry 7(4):251-60
11. Angst J, Wicki W. 1991. The Zurich study, XI. Is dysthymia a separate form of depression? Results of the Zurich Cohort Study. Eur. Arch. Psychiatry Clin. Neurosci. 240:349-54
12. Ascher JA, Cole JO, Colin J-N, Feighner JP, Ferris RM, et al. 1995. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56(9):395-401
13. Baldessarini RJ, Tondo L, Hennen J, Viguera AC. 2002. Is lithium still worth using? An update of selected recent research. Harv. Rev. Psychiatry 10:59-75
14. Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP. 2005. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: Argos study. Depress. Anxiety 22(2):68-76
15. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, et al. 2007. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin. Ther. 29(5):918-26
16. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, et al. 2007. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J. Biol. Psychiatry 8(2):67-104
17. Bauer M, Whybrow PC, Angst J, Versiani M, Müller H-J, WFSBP Task Force on Treat. Guidel. Unipolar Depressive Disord. 2002. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry 3(1):5-43
18. Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, et al. 1991. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br. Med. J. 303:685-92
19. Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, et al. 2006. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J. Clin. Psychopharmacol. 26:75-78
20. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, et al. 2007. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(6):843-53
21. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. 2002. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am. J. Psychiatry 159(6):1005-10
22. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, et al. 2000. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry 57(5):481-89
23. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, et al. 2003. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 60:392-400
24. Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, et al. 2006. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J. Clin. Psychiatry 67(10):1501-10
25. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, et al. 2007. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment - a meta-analysis of randomized controlled trials. JAMA 297(15):1683-96
26. Buckley NA, McManus PR. 2002. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. Br. Med. J. 325:1332-33
27. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, et al. 2003. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64:1013-24
28. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162(7):1351-60
29. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354(6):579-87
30. Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR. 2006. Are all antidepressants really the same? The case of fluoxetine: a systematic review. J. Clin. Psychiatry 67(6):850-64
31. Clayton AH. 2007. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert Opin. Pharmacother. 8(4):457-66
32. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, et al. 2006. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295(5):499-507
33. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. 2006. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety 23(6):364-72
34. Cousins DA, Young AH. 2007. The armamentarium of treatments for bipolar disorder: a review of the literature. Int. J. Neuropsychopharmacol. 10(3):411-31
35. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, et al. 2006. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J. Pharmacol. Exp. Ther. 318(2):657-65
36. Delgado PL. 2004. How antidepressants help depression: mechanisms of action and clinical response. J. Clin. Psychiatry 65(Suppl. 4):25-30
37. Depress. Guideline Panel. 1993. Depression in Primary Care. Vol. 2. Treatment of Major Depression. Clinical Practice Guideline No. 5. Rockville, MD: U.S. Dep. Health Hum. Serv. Agency Health Care Policy Res. AHCPR Publ. 93-0551
38. Dubicka B, Hadley S, Roberts C. 2006. Suicidal behaviour in youths with depression treated with new-generation antidepressants - meta-analysis. Br. J. Psychiatry 189:393-98
39. Duman RS, Heninger GR, Nestler EJ. 1997. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54:597-606
40. Duman RS, Monteggia LM. 2006. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59(12):1116-27
41. Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW. 2002. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 49:1-10
42. Edwards JG, Anderson I. 1999. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57(4):507-33
43. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, et al. 2005. Bupropion HCl: 15 years of clinical experience. Prim. Care Companion J. Clin. Psychiatry 7:106-13
44. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, et al. 2006. STAR* D Study Team. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am. J. Psychiatry 163(7):1161-72
45. Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, et al. 2001. Reemergence of sexual dysfunction in patients with major depressive disorder: double blind comparison of nefazodone and sertraline. J. Clin. Psychiatry 62(1):24-29
46. Foley KF, DeSanty KP, Kast RE. 2006. Bupropion: pharmacology and therapeutic applications. Expert Rev. Neurother. 6(9):1249-65
47. Frampton JE, Plosker GL. 2007. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 21(7):581-609
48. Franchini L, Gasperini M, Zanardi R, Smeraldi E. 2000. Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate. J. Affect. Disord. 58:233-36
49. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, et al. 1990. Three-year outcomes for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 47:1093-99
50. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, et al. 1993. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J. Affect. Disord. 27:139-45
51. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, et al. 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry 48(9):851-55
52. Frank E, Thase ME. 1999. Natural history and preventative treatment of recurrent mood disorders. Annu. Rev. Med. Sci. Top. Clin. Sci. 50:453-68
53. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, et al. 2003. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653-61
54. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. 2006. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am. J. Psychiatry 163(11):1898-904
55. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. 2004. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry 161(9):1537-47
56. Golden RN, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, et al. 2005. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am. J. Psychiatry 162(4):656-62
57. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. 2003. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290(11):1467-73
58. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, et al. 2004. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry 65(3):432-41
59. Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, et al. 2007. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. Br. Med. J. 335(7611):142-46
60. Guelfi JD, Ansseau M, Timmerman L, Kørsgaard S, The Mirtazapine-Venlafaxine Study Group. 2001. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J. Clin. Psychopharmacol. 21(4):425-31
61. Gupta S, Nihalani N, Masand P. 2007. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann. Clin. Psychiatry 19(2):125-32
62. Gutman DA, Owens MJ. 2006. Serotonin and norepinephrine transporter binding profile of SSRIs. Essent. Psychopharmacol. 7(1):35-41
63. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, et al. 2003. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28:1374-82
64. Haddad PM. 2001. Antidepressant discontinuation syndromes: clinical relevance, prevention and management. Drug Safety 24(3):183-97
65. Hamilton M. 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56-62
66. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, et al. 2007. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med. 167(12):1246-51
67. Hendrick V, Altshuler L. 2002. Management of major depression during pregnancy. Am. J. Psychiatry 159(10):1667-73
68. Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ. 2005. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J. Clin. Psychiatry 66(4):455-68
69. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, et al. 1998. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch. Gen. Psychiatry 55:694-700
70. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, et al. 2003. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorders. Arch. Gen. Psychiatry 60:261-69
71. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, et al. 2002. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59(6):530-37
72. Kapur S, Mieczkowski T, Mann JJ. 1992. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 268:3441-45
73. Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, et al. 2006. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 67(4):626-37
74. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, et al. 2006. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59(3):216-23
75. Keller MB. 2003. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289(23):3152-60
76. Keller MB, Boland RJ. 1998. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol. Psychiatry 44(5):348-60
77. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, et al. 2007. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two years (PREVENT) Study: outcomes from the 2-year and combined maintenance phases. J. Clin. Psychiatry 68(8):1246-56
78. Kendler KS, Thornton LM, Gardner CO. 2001. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am. J. Psychiatry 158:582-86
79. Kennedy SH, Andersen HF, Lam RW. 2006. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci. 31(2):122-31
80. Kessing LV, Hansen MG, Andersen PK, Angst J. 2004. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders - a life-long perspective. Acta Psychiatr. Scand. 109(5):339-44
81. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, et al. 2006. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry 163(9):1561-68
82. Kessler RC, Merikangas KR, Wang PS. 2007. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu. Rev. Clin. Psychol. 3:137-58
83. Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. 2007. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin. Drug Investig. 27(7):481-92
84. Kocsis JH, Rush AJ, Markowitz JC, Borian FE, Dunner DL, et al. 2003. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacol. Bull. 37(4):73-87
85. Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, et al. 2007. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J. Clin. Psychiatry 68(7):1014-23
86. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, et al. 2001. Sertraline versus imipramine to prevent relapse in chronic depression. J. Affect. Disord. 65:27-36
87. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, et al. 2006. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90(2):451-59
88. Kupfer DJ. 1991. Long-term treatment of depression. J. Clin. Psychiatry 52(Suppl. 5):28-34
89. Kupfer DJ. 2005. The increasing medical burden in bipolar disorder. JAMA 293:2528-30
90. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, et al. 1992. Five-year outcome for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 49:769-73
91. Kurian BT, Arbogast PG, Ray WA, Fuchs DC, Cooper WO. 2006. Effect of government regulatory changes on SSRI prescriptions in children. Pharmacoepidemiol. Drug Saf. 15:S16
92. Kushner SF, Khan A, Lane R, Olson WH. 2006. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 8(1):15-27
93. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. 2007. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry 68(6):899-907
94. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, et al. 2006. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry 163(2):232-39
95. Lotufo-Neto F, Trivedi M, Thase ME. 1999. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine in the treatment of depression. Neuropsychopharmacology 20(3):226-47
96. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. 2007. Specific SSRIs and risk of specific birth defects. Am. J. Epidemiol. 165(11):S148
97. Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, et al. 2006. ACNP task force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 31(3):473-92
98. March J, Silva S, Petrycki S, Curry J, Wells K, et al. 2004. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression - Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 292(7):807-20
99. McCullough JP Jr, Klein DN, Borian FE, Howland RH, Riso LP, et al. 2003. Group comparisons of DSM-IV subtypes of chronic depression validity of the distinctions, Part 2. J. Abnorm. Psychol. 112(4):614-22
100. McCullough JP Jr, Klein DN, Keller MB, Holzer CEI, Davis SM, et al. 2000. Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (double depression): validity of the distinction. J. Abnorm. Psychol. 109(3):419-27
101. McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, et al. 2007. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord. 9(4):426-34
102. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, et al. for the STAR*D Trial Team. 2006. A comparison of tranylcypromine to the combination of venlafaxine-XR plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am. J. Psychiatry 163(9):1531-41
103. McKeown RE, Cuffe SP, Schulz RM. 2006. US suicide rates by age group, 1970-2002: an examination of recent trends. Am. J. Public Health 96(10):1744-51
104. Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, Klimkeit E. 2006. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J. Am. Acad. Child Adolesc. Psychiatry 45(10):1151-61
105. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, et al. 1998. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline and imipramine. J. Clin. Psychiatry 59(11):608-19
106. Mintz J, Mintz LI, Arruda MJ, Hwang SS. 1992. Treatments of depression and the functional capacity to work. Arch. Gen. Psychiatry 49(10):761-68
107. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134:382-89
108. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, et al. 2005. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293(19):2372-83
109. Mulrow CD, Williams JW Jr, Trivedi M. 1999. Treatment of Depression: Newer Pharmacotherapies. AHCPR Publ. 99-E014. Rockville, MD: Agency Health Care Policy Res.
110. Murray CJL, Lopez AD. 1996. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 274(5288):740-41
111. Nelson JC, Mazure CM, Bowers MB, Jatlow PI. 1991. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 48:303-7
112. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. 2007a. Comprehensive analysis of remission (COMPARE) with venlafaxine vs SSRIs. Biol. Psychiatry. In press
113. Nemeroff CB, Kalali A, Keller MB, Charney DS, Lenderts SE, et al. 2007b. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch. Gen. Psychiatry 64(4):466-72
114. Newcomer JW. 2007. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 68:20-27
115. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, et al. 2007. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a noninferiority study. Curr. Med. Res. Opin. 23(2):401-16
116. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. 2002. National trends in the outpatient treatment of depression. JAMA 287(2):203-9
117. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. 2000. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2(3 Pt. 2):249-55
118. Papakostas GI, Fava M. 2006. A meta-analysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can. J. Psychiatry 51(12):783-90
119. Papakostas GI, Fava M. 2007. A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur. Neuropsychopharm. In press
120. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. 2006. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol. Psychiatry 60(12):1350-55
121. Papakostas GI, Shelton RC, Smith J, Fava M. 2007a. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J. Clin. Psychiatry 68(6):826-31
122. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. 2007b. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? Biol. Psychiatry. In press
123. Papakostas GI, Trivedi MH, Alpert JE, Seifert CA, Krishen A, et al. 2007c. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J. Psychiatr. Res. In press
124. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. 1995. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 25(6):1171-80
125. Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, et al. 1999. Prevention of relapse in residual depression by cognitive therapy. Arch. Gen. Psychiatry 56(9):829-35
126. Perahia DGS, Pritchett YL, Kajdasz DK, Bauer M, Jain R, et al. 2007. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J. Psychiatr. Res. In press
127. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. 2006. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry 67(4):509-16
128. Pfeffer CR. 2007. The FDA pediatric advisories and changes in diagnosis and treatment of pediatric depression. Am. J. Psychiatry 164(6):843-46
129. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. 2007. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am. J. Psychiatry 164(7):1035-43
130. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, et al. 2006. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry 189:124-31
131. Preskorn SH. 1995. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry 56(Suppl. 6):12-21
132. Prince M, Patel V, Saxena S, Maj M, Maselko J, et al. 2007. No health without mental health. Lancet 370(9590):859-77
133. Quitkin FM, Taylor BP, Kremer C. 2001. Does mirtazapine have a more rapid onset than SSRIs? J. Clin. Psychiatry 62(5):358-61
134. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, et al. 2006. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31:2505-13
135. Reed RC, Dutta S. 2006. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? Ther. Drug Monit. 28(3):413-18
136. Reynolds CF III, Frank E, Perel JM, Imber SD, Cornes C, et al. 1999. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression. A randomized controlled trial in patients older than 59 years. JAMA 281(1):39-45
137. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, et al. 2007. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med. 167(2):188-94
138. Riso LP, Thase ME, Howland RH, Friedman ES, Simons AD, Tu XM. 1997. A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. J. Affect. Disord. 43:131-42
139. Robinson DS, Amsterdam JD. 2007. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J. Affect. Disord. In press
140. Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, et al. 1998. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol. Psychiatry 44(1):3-14
141. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, et al. 2006a. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31(9):1841-53
142. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, et al. 2006b. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354(12):1231-42
143. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, et al. 2006. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J. Psychopharmacol. 20(4):536-46
144. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, et al. 2007. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 356(17):1711-22
145. Shelton RC. 2003. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin. Pharmacother. 4(7):1175-83
146. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, et al. 2001. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158(1):131-34
147. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, et al. 2005. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66(10):1289-97
148. Simon GE. 2006. The antidepressant quandary - considering suicide risk when treating adolescent depression. N. Engl. J. Med. 355(26):2722-23
149. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. 2002. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry 180(5):396-404
150. Spigset A, Hagg S, Bate A. 2003. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int. Clin. Psychopharmacology 18(3):157-61
151. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. 2002. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 26(4):530-36
152. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. 2006. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol. Rev. 58(1):115-34
153. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, et al. 1995. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J. Clin. Psychiatry 56(Suppl. 6):3-11
154. Teicher MT, Glod C, Cole JO. 1990. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am. J. Psychiatry 147(2):207-10
155. Thase ME. 1998. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry 59(10):502-8
156. Thase ME. 2005. Bipolar depression: issues in diagnosis and treatment. Harv. Rev. Psychiatry 13(5):257-71
157. Thase ME. 2006a. Bipolar depression: diagnostic and treatment considerations. Dev. Psy chopathol. 18(4):1213-30
158. Thase ME. 2006b. Mirtazapine. In Kaplan & Sadock's Comprehensive Textbook of Psychiatry, ed. BJ Sadock, VA Sadock, pp. 2851-53. New York: Williams & Wilkins
159. Thase ME. 2006c. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr. 11(12 Suppl. 15):12-21
160. Thase ME. 2007. Recognition and diagnosis of atypical depression. J. Clin. Psychiatry 68(Suppl. 8):11-16
161. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. 2006a. A double-blind comparison between bupropion XL and venlafaxine XR - sexual functioning, antidepressant efficacy, and tolerability. J. Clin. Psychopharmacol. 26(5):482-88
162. Thase ME, Entsuah AR, Rudolph RL. 2001. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178:234-41
163. Thase ME, Friedman ES. 1999. Is psychotherapy an effective treatment for melancholia and other severe depressive states? J. Affect. Disord. 54:1-19
164. Thase ME, Friedman ES, Howland RH. 2000. Venlafaxine and treatment-resistant depression. Depress. Anxiety 12(Suppl. 1):55-62
165. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, et al. 2005a. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J. Clin. Psychiatry 66(8):974-81
166. Thase ME, Jindal RD, Howland RH. 2002. Biological aspects of depression. In Handbook of Depression, ed. IH Gotlib, CL Hammen, 8:192-218. New York: Guilford
167. Thase ME, Kupfer DJ. 1996. Recent developments in the pharmacotherapy of mood disorders. J. Consult. Clin. Psychol. 64(4):646-59
168. Thase ME, MacFadden W, Weisler RH, Chang W, Paulsson B, et al. 2006b. Efficacy of quetiapine monotherapy in bipolar I and II depression - a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 26(6):600-9
169. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. 2007. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparators as assessed by remission rates in patients with major depressive disorder. J. Clin. Psychopharmacol. In press
170. Thase ME, Shelton RC, Khan A. 2006c. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance - a randomized comparison of standard- and higher-dosing strategies. J. Clin. Psychopharmacol. 26(3):250-58
171. Thase ME, Simons AD, McGeary J, Cahalane JF, Hughes C, et al. 1992. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am. J. Psychiatry 149(8):1046-52
172. Thase ME, Sloan DME. 2006. Venlafaxine. In Essentials of Clinical Psychopharmacology, ed. AF Schatzberg, CB Nemeroff, pp. 159-70. Washington, DC: Am. Psychiatr. Assoc.
173. Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ. 2005b. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol. 25(2):132-40
174. Thase ME, Trivedi MH, Rush AJ. 1995. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12:185-219
175. Thomson Healthcare Inc. 2006. Physician's Desk Reference. Montvale, NJ: Thomson Healthcare
176. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, et al. 2006. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry 163(2):247-56
177. Tohen M, Chengappa KNR, Suppes T, Zarate CA Jr, Calabrese JR, et al. 2002. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate of lithium monotherapy. Arch. Gen. Psychiatry 59(1):62-69
178. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, et al. 2005. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry 162(7):1281-90
179. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, et al. 2003. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry 160(7):1263-71
180. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, et al. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163(1):28-40
181. Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, et al. 2002. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry 63(6):508-12
182. Wade A, Gembert K, Florea I. 2007. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin. 23(7):1605-14
183. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH. 2005. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 66(3):323-30
184. Wilson KC, Mottram PG, Ashworth L, Abou-Saleh MT. 2003. Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study. Br. J. Psychiatry 182:492-97